TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Change in Directorate
Change in Directorate24-05-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Change in Directorate
Change in DirectorateTORRENT PHARMACEUTICALS LTD. - 500420 - Corporate Action-Board approves Dividend
Dividend UpdatesTORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentationTORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Outcome Of Board Meeting Dated 24-May-24
Outcome of Board meeting dated 24-May-24TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of share certificateTORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31-Mar-24TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post Quarterly Financial Result Conference call with investors / analystTORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 ,inter alia, to consider and approve We would like to inform you that: 1. A meeting of the Board of Directors will be held on Friday, 24-May-24, inter alia, to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-24. 2. In the above meeting, the Board would also consider the following: i. Recommendation of final dividend, if any, on the equity shares of the Company, for the year 2023-24. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders'' approval in the ensuing Annual General Meeting. Kindly take note of the above.